紫杉醇/顺铂(Paclitaxel/Cisplatin) - 药物靶点：DNA x Tubulin_专利_临床

概要

基本信息

药物类型

小分子化药

别名

TP

靶点

DNA x Tubulin

作用方式

抑制剂

作用机制

DNA抑制剂(DNA抑制剂)、微管蛋白抑制剂、DNA烷化剂

+ [2]

治疗领域

肿瘤

在研适应症-

非在研适应症

局部晚期头颈部鳞状细胞癌

原研机构

天津市肿瘤研究所

在研机构-

非在研机构

天津市肿瘤研究所

权益机构-

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

结构/序列

分子式C47H51NO14

InChIKeyRCINICONZNJXQF-MZXODVADSA-N

CAS号33069-62-4

查看全部结构式(2)

关联

15

项与紫杉醇/顺铂相关的临床试验

NCT06588335

/ Not yet recruiting临床2期IIT

A Single-Center, Exploratory Study of BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

This is a single-center, single-arm, phase II study, aiming to preliminarily explore the efficacy and safety of JS004 combined with toripalimab and chemotherapy for perioperative treatment of locally advanced thoracic esophageal squamous cell carcinoma that is resectable. The plan is to enroll 20 patients with locally advanced resectable thoracic esophageal cancer. In the neoadjuvant treatment phase, patients will receive JS004 + toripalimab + chemotherapy (paclitaxel + cisplatin) for 2 cycles. This will be followed by the surgical phase: surgery will be performed 3-8 weeks after the last dose of neoadjuvant treatment. In the postoperative maintenance treatment phase, maintenance treatment will start 4 weeks ± 7 days after surgery, but no later than 10 weeks after surgery. For patients with R0 resection confirmed by postoperative pathology, they will receive maintenance treatment with JS004 + toripalimab for up to 15 cycles. For patients with non-R0 resection, they will receive maintenance treatment with JS004 + toripalimab combined with standard radiation or chemotherapy (selected by the investigator based on esophageal cancer guidelines). During the study, the maximum number of cycles of JS004 combined with toripalimab is 17 cycles (approximately 1 year).

开始日期2024-09-30

申办/合作机构

河南省人民医院

NCT06444009

/ Recruiting临床2期IIT

Neoadjuvant Immunotherapy in Combination With Chemotherapy in Resectable Head and Neck Cancer：A Randomized, Phase II Study

A Randomized, Phase II Study of ivonescimab or cadonilimab or penpulimab in Combination With Cisplatin and Nab-paclitaxel in Patients With locally advanced head and neck squamous cell carcinoma (HNSCC) eligible for resection.
This proposed study will evaluate the efficacy and safety of preoperative administration of ivonescimab or cadonilimab or penpulimab combined with chemotherapy in HNSCC who are eligible for resection.

开始日期2024-07-01

申办/合作机构

四川大学华西医院（四川省国际医院）

NCT05520619

/ Active, not recruiting临床2期IIT

Tislelizumab Plus Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: a Phase II, Randomized Trial (EC-CRT-002)

Definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable locally advanced esophageal cancer (EC). However, as high as more than 40% of EC patients experienced locoregional recurrence after concurrent CRT. Immunotherapy targeting the PD-1/PD-L1 checkpoints has demonstrated promising activity in advanced EC. Recently, the combination of immunotherapy with CRT has emerged as a promising strategy to improve clinical outcomes in EC. The aim of this study was to evaluate whether the efficacy of tislelizumab (an anti-PD-1 antibody) plus induction chemotherapy followed by concurrent chemoradiotherapy would achieve a ≥71% 1-year progression-free survival rate, surpassing the historical 56% rate (NCT02403531) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).

开始日期2022-09-15

申办/合作机构

中山大学

[+2]

100 项与紫杉醇/顺铂相关的临床结果

登录后查看更多信息

100 项与紫杉醇/顺铂相关的转化医学

登录后查看更多信息

100 项与紫杉醇/顺铂相关的专利（医药）

登录后查看更多信息

251

项与紫杉醇/顺铂相关的文献（医药）

2025-04-18·The Angle Orthodontist

Effects of chemotherapeutic vs regular toothpastes on dental plaque and gingival inflammation in orthodontic patients with fixed appliances: a systematic review and meta-analysis

Article

作者: Liu, Yinli ; Valkenburg, Cees ; Slot, Dagmar Else ; Jonkman, Ronald Edwin Gaston

ABSTRACTObjectivesTo analyze, appraise, and synthesize papers in which authors have compared the effects of chemotherapeutic toothpaste (CTP) and regular toothpaste (RTP) on plaque scores (PSs), gingival scores (GSs), and bleeding scores (BSs) in orthodontic patients wearing fixed appliances (FAs).Materials and MethodsPubMed-MEDLINE, Cochrane-CENTRAL, and Embase databases were searched with predefined search terms until April 2024 for controlled or randomized controlled clinical trials aligning with the aim. In the eligible papers, risk of bias was evaluated, data of interest were extracted, and a descriptive analysis was performed. If possible, meta-analyses and subanalyses on specific factors were conducted. The quality of evidence and strength of the recommendation were rated.ResultsIn our search and selection, we obtained five papers describing eight comparisons. Potential risk of bias was assessed as some concerns to high, and heterogeneity was considered substantial. Descriptive analysis revealed no significant difference in PS and BS, with an improvement in GS favoring CTP. Meta-analyses of the end scores showed CTP significantly reduced PS (standardized mean difference [SMD] = −0.26; 95% confidence interval [CI] = −0.52, −0.01; P = .04). However, no significant effects were observed on GS and BS. These findings were supported by the subanalyses on CTP with chlorhexidine (CHX; PS: mean difference [MD] = −5.12; 95% CI = −10.08, −0.15; P = .04). The quality of evidence was graded as very low, and strength of the recommendation was judged as very weak.ConclusionsFor orthodontic patients with FAs, very weak certainty exists in recommending CTP (eg, with CHX) over RTP for use with toothbrushing. CTP may have a very small effect on PS and a small effect on GS.

2025-03-01·Pesticide Biochemistry and Physiology

A comparative study of the controllable release and insecticidal efficacy for two typical carrier methods on diamide insecticide delivery system

Article

作者: Huang, Yucong ; Yang, Huiying ; Liu, Xingyu ; Liu, Bingrui ; Li, Yahui ; Li, Shaochen

Using nano/microcarriers of pesticides in sustainable pest management represents a promising strategy for enhancing pesticide efficiency while mitigating environmental harm. The reported pesticide loading methods include one-step self-assembly encapsulation and two-step absorption loading, but the controllable release and insecticidal efficacy of these two methods have been infrequently evaluated. Herein, the typical diamide insecticide cyantraniliprole (CTP) was employed as the model pesticide. A hydrogen bond-driven one-step self-assembly method and a chemical deposition method were utilized to fabricate highly dispersed polylactic acid (PLA) microspheres and calcium carbonate (CaCO₃) microspheres. The resulting CTP-loaded PLA microspheres (CTP-PLA MS) and CaCO₃ microspheres (CTP-CaCO₃ MS) both exhibited high adhesion, resistance to rain erosion, and insecticidal activity under laboratory conditions. However, the functional CTP-PLA MS demonstrated superior sustained pesticide release performance, higher pesticide loading capacity, and less application amount than that of CTP-CaCO₃ MS. At the same time, the acute toxicity of CTP-PLA MS exhibited slightly reduced acute toxicity to honeybees (Apis mellifera), signifying enhanced biocompatibility. Finally, the CTP-PLA MS maintained superior insecticidal efficacy than the normal CTP in controlling O. nubilalis at a low concentration. The present study represents a promising pesticide carrier as a highly efficient, eco-friendly agent for sustained management of O. nubilalis.

2025-03-01·Reproductive Toxicology

Hormonal mechanism and pathogenetic therapy of citalopram-induced infertility in female rats

Article

作者: Suleyman, Halis ; Suleyman, Bahadir ; Gumusburun, Neset ; Mendil, Ali Sefa ; Bakan, Nuri ; Bulut, Seval ; Delibasi, Ilhan Bahri ; Yilmaz, Betul Kalkan ; Altuner, Durdu ; Mammadov, Renad

Citalopram is a selective serotonin reuptake inhibitor (SSRI) and has been associated with reproductive dysfunction in women. In this study, the effects of citalopram on reproductive health in female rats were investigated. Albino Wistar rats was divided into six groups (each group/n = 12): healthy (HG), citalopram (CTP), cabergoline (CBR), metyrapone (MTP), cabergoline+citalopram (CBR+CTP), and metyrapone+citalopram (MTP+CTP). Initially, cabergoline 0.1 mg/kg and metyrapone 50 mg/kg were administered orally. A dose of 10 mg/kg of citalopram was given orally one hour later. For 30 days, the treatment protocol was applied once a day. Then, blood samples were taken from the tail veins of six rats from each group for prolactin and corticosterone analyses and ovaries were removed after euthanasia. The ovaries were examined for oxidants and antioxidants and histopathologically. During two months, the remaining animals were kept with male rats. The rats that did not deliver during this period were considered infertile. In terms of oxidants and antioxidants, there was no significant difference between the groups (p > 0.05). In half of the female rats, citalopram caused infertility, increased levels of prolactin and corticosterone, and damaged the ovaries histopathologically (p < 0.05). Cabergoline suppressed the elevation of prolactin by citalopram (p < 0.001) but did not prevent infertility. In contrast, metyrapone significantly prevented the citalopram-induced increase in corticosterone, infertility, and tissue damage induced by citalopram (p < 0.05). According to the results of our study, the preventive effect of drugs that suppress excessive corticosterone on citalopram-induced infertility in rats may be encouraging for further clinical studies.

100 项与紫杉醇/顺铂相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局部晚期头颈部鳞状细胞癌	临床2期	中国	天津市肿瘤研究所	2021-11-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO_ASIA2023	N/A	局部晚期头颈部鳞状细胞癌新辅助	21	Pembrolizumab plus TP	(選鹽壓淵簾鏇醖艱壓鏇) = 選淵鑰鑰選鬱齋鑰選觸齋鏇壓壓製糧構廠網遞 (築願鏇鏇鬱製鬱廠鹽夢 ) 更多	-	2023-12-02
ESMO_ASIA2023	N/A	局部晚期头颈部鳞状细胞癌新辅助	21	Pembrolizumab plus DP	(選鹽壓淵簾鏇醖艱壓鏇) = 觸壓夢簾鑰憲簾糧鹽鬱齋鏇壓壓製糧構廠網遞 (築願鏇鏇鬱製鬱廠鹽夢 ) 更多	-	2023-12-02
ASCO2016	临床2期	复发性宫颈癌	65	Cisplatin-Paclitaxel regimen	(蓋膚選襯鏇鬱願膚簾衊) = 糧蓋壓廠鬱鏇衊範鑰醖壓夢觸鬱蓋獵憲糧鑰鹽 (鹽願繭繭衊簾窪積積製 ) 更多	积极	2016-05-20
ASCO2015	N/A	局部晚期头颈部鳞状细胞癌	-	Paclitaxel 80 mg/m2 plus cisplatin 75 mg/m2	(廠築築鑰糧憲廠鏇糧壓) = 選蓋獵顧夢糧繭餘鏇憲夢膚餘遞淵膚艱製選繭 (醖鬱範襯糧遞構夢憲壓 ) 更多	-	2015-05-20
ASCO2014	N/A	阴茎鳞状细胞癌	41	Paclitaxel plus cisplatin	(構簾觸壓壓蓋築網夢襯) = 獵艱夢築醖積鏇膚廠糧齋襯築顧積廠製構夢顧 (鹽餘淵鹹構獵衊鹹膚憲 ) 更多	-	2014-05-20
ASCO_GU2014	N/A	阴茎鳞状细胞癌辅助 \| 新辅助	47	Paclitaxel plus cisplatin and 5-fluorouracil (T-PF)	(鬱襯製鑰鬱襯膚窪鹽艱) = 願鹽衊網壓鬱淵齋網簾觸鑰構構窪繭壓觸鏇鑰 (憲艱鬱觸醖壓鬱顧襯醖 )	-	2014-02-01
WCLC2013	N/A	晚期鳞状细胞肺癌	32	Docetaxel/cisplatin chemotherapy and thoracic radiotherapy	(憲鑰蓋積蓋獵網構餘鑰) = 積選築窪齋廠鏇鹽鬱構鏇選醖膚鏇襯夢鏇夢獵 (顧積選積憲齋鹽鹹夢廠, 63 ~ 97) 更多	-	2013-10-29
ASCO2013	N/A	晚期食管鳞状细胞癌	133	Paclitaxel plus cisplatin	(構糧獵願遞衊積鏇鹹選) = 淵淵鹹鑰範艱築廠鑰蓋鹹餘艱糧網繭顧顧遞鑰 (鏇淵鏇選艱醖願鹽觸觸, 5.68 ~ 8.32) 更多	-	2013-05-20
ASCO2013	N/A	局部晚期宫颈癌	47	Cisplatin, paclitaxel, and capecitabine	齋觸製齋簾淵夢繭衊築(簾鹹糧蓋齋範遞觸顧廠) = 廠鬱齋築鑰艱齋鬱觸夢製衊網獵製壓襯淵積鏇 (鑰蓋鬱遞壓糧遞淵網積 ) 更多	-	2013-05-20
ASCO2011	N/A	转移性胃癌一线 \| 二线	75	Paclitaxel, cisplatin, and fluorouracil (PCF)	(艱範簾醖遞繭選醖憲顧) = 壓製蓋簾襯繭艱蓋淵簾憲襯鏇選鹹淵構餘觸淵 (衊衊壓願鹹鬱範觸衊憲 ) 更多	-	2011-05-20
ASCO2011	临床2期	非小细胞肺癌	-	Paclitaxel plus cisplatin	(衊衊齋醖觸糧構築夢窪) = 範醖壓網糧醖遞淵夢鏇鹽窪鏇壓構膚艱壓簾繭 (繭淵廠積願積願膚築鹹 ) 更多	积极	2011-05-20
ASCO2011	临床2期	非小细胞肺癌	-	Paclitaxel plus cisplatin with Cadi-05	(衊衊齋醖觸糧構築夢窪) = 選糧蓋蓋鏇獵獵選觸遞鹽窪鏇壓構膚艱壓簾繭 (繭淵廠積願積願膚築鹹 ) 更多	积极	2011-05-20